Current Report Filing (8-k)
November 18 2021 - 07:06AM
Edgar (US Regulatory)
0001684144false00016841442021-11-162021-11-16iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
November 16, 2021
ZOMEDICA CORP.
|
(Exact name of
registrant as specified in its charter)
|
Alberta,
Canada
|
|
001-38298
|
|
N/A
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
100 Phoenix
Drive, Suite 125, Ann Arbor, Michigan
|
|
48108
|
(Address of
principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: (734)
369-2555
N/A
|
(Former name or
former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on
which registered
|
Common Shares, without
par value
|
ZOM
|
NYSE American
|
Item 8.01 Other Events.
Three directors, one executive officer and certain other employees
of Zomedica Corp. and its subsidiaries (collectively, the
“Company”) have adopted trading plans pursuant to Rule 10b5-1 of
the Securities Exchange Act of 1934, as amended (the “Plans”). The
Plans cover the period of January 1, 2022 through December 31, 2022
and were entered into for a variety of reasons including long-term
financial planning, retirement planning, and diversification
purposes.
Under Rule 10b5-1, directors, officers, and other employees who may
be exposed from time to time to material non-public information may
adopt a pre-arranged plan or contract at a time when they are not
in possession of material non-public information for the sale of
company securities under specified conditions and at specified
times. Using these 10b5-1 plans, individuals gradually can
diversify their investment portfolios, spread stock trades out over
an extended period of time to reduce market impact, and avoid
concerns about transactions occurring at a time when they might
possess material non-public information. A Rule 10b5-1 plan also
may allow an insider to exercise, on specific future dates, a stock
option that may be nearing expiration, and simultaneously sell some
or all of the shares underlying the option to generate the cash
needed to pay the exercise price of the option and related income
tax obligations. The Plans cover a maximum of 8,061,842 common
shares of the Company, including 7,101,842 common shares of the
Company issuable upon the exercise of outstanding stock options;
however, some, none or all of those common shares ultimately may be
sold depending on the terms of the individual Plans and the trading
price of the Company’s common shares.
Transactions under the Plans will be reported to the Securities and
Exchange Commission in accordance with applicable securities laws,
rules, and regulations, to the extent applicable. The Company does
not undertake to report Rule 10b5-1 plans that may be adopted by
any directors, officers or other employees in the future, or to
report any modifications or termination of any publicly announced
trading plan, except to the extent required by law.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
ZOMEDICA CORP. |
|
|
|
|
|
Date: November 18, 2021 |
By: |
/s/ Ann Marie
Cotter |
|
|
Name:
|
Ann Marie Cotter |
|
|
Title: |
Chief Financial Officer |
|
Zomedica (AMEX:ZOM)
Historical Stock Chart
From Apr 2022 to May 2022
Zomedica (AMEX:ZOM)
Historical Stock Chart
From May 2021 to May 2022